Infectious Disease Services

Contact Us

Our infectious disease drug development services team delivers the highest quality, full-service contract research to support the pharmaceutical and biotechnology sectors. Southern Research can assist you in preclinical drug development of antibiotics, antivirals, antifungals, vaccines, and topical microbiocides. SR was the first laboratory to offer GLP-compliant testing of vaccines for highly pathogenic avian influenza (HPAI) and has supported numerous clinical trials in our serology group. SR scientists have conducted major international screening programs for tuberculosis, SARS, hepatitis, HIV, dengue and influenza, including HPAI. Our scientists are experienced in animal model efficacy testing and our facilities have capability in aerobiology and BSL3 containment. We are a recognized expert in infectious disease biology and pathogenesis.



Since the SARS epidemic of 2002-2003, SR has built a mature SARS-coronavirus program that includes a primary cytopathic effect (CPE) assay in low- and high-throughput formats, as well as secondary plaque assays. SR is currently approved to acquire and work with clinically relevant BSL-3 isolates including coronavirus 2 (SARS-CoV-2) or informally known as the Wuhan coronavirus. SR scientists and partners are also looking at ways of quickly repurposing existing antiviral drugs to see whether any might work against the SARS-CoV-2.

SR COVID fact sheet

SR-0312COVID-19 Hamster Model (IDR) One-pager Final

  • Experience with a Wide Variety of Pathogens
    • Influenza viruses (seasonal, HPAI)
    • Dengue
    • Zika
    • Hepatitis B/C
    • HIV
    • RSV
    • SARS
    • Pox viruses
    • Herpes viruses
    • Hantavirus
    • Other respiratory and enteric viruses
    • Methicillin-resistant Staphylococcus aureus (MRSA)
    • TB (including multi-drug resistant)
    • Other bacterial and fungal pathogens
    • Multidrug-resistant Gram-negative bacteria
    • ESKAPE bacteria
    • STI bacteria
  • Services
    • Anatomic pathology
    • Clinical pathology
    • High-speed cell sorting/flow cytometry
    • Bacterial identification and culture
    • Antimicrobial susceptibility testing: MIC/MBC
    • Biofilm inhibition testing
    • Hemagglutination inhibition (high throughput capability)
    • Microneutralization (high throughput capability)
    • Virus purification and characterization
    • Reagent development
    • Quantitative PCR
    • Immunologic assays
    • Custom assays
  • In Vitro Programs
    • Compound screening
    • Target selection
    • Mechanism of action
    • Infectious disease research
    • Immunologic/seriologic testing
    • Virologic studies
    • Bacteriologic studies
    • Drug resistance
    • Topical microbicide screening
    • Disinfectant/antiseptic testing
  • In Vivo Programs
    • Animal models – murine, porcine, canine, rabbit, ferret, NHP, and others upon request
    • Efficacy testing of vaccines and therapeutics
    • Pathogenesis
    • Topical microbiocide testing
  • Clinical Trial Support

    Available via the most advanced technologies to help meet your therapeutic/vaccine clinical trial requirements and monitor the effect of your candidate by:

    • Quantitative PCR
    • Serotyping
    • Genotyping
    • Immunogenicity studies
    • Serum drug levels
    • Biomarker analysis

How To Work With Us

As a CRO service provider, Southern Research’s Drug Development division has a straightforward business model. Once you contact our business development representative, a confidentiality disclosure agreement will be initiated (your agreement or ours) to facilitate detailed discussions around your specific needs. One of our subject matter experts will be brought into the discussion to ensure we have a comprehensive understanding of your project. A proposal will then be prepared, outlining the tasks to be accomplished, along with a budget and timeline. Upon acceptance of the proposal, a contract will be provided to establish the legal framework for the project.

HIV/AIDS Research

Southern Research joined the front lines in the battle against HIV/AIDS in 1986, not long after the deadly viral infection emerged in the U.S. as a terrifying new public health threat. Over the years, our innovative scientists have supported drug and vaccine discovery and development efforts led by industry and government partners. As a result of this longstanding dedication to fight HIV/AIDS, Southern Research has helped 90% of all currently approved antivirals get to market. Today we continue to offer developers one-of-a-kind solutions from high-throughput screening systems, to our unique collection of drug resistant clinical HIV isolates, to the newly fielded Quantitative Viral Outgrowth Assay (QVOA), the only universally accepted assay for measuring the frequency of latently infected cells in patients receiving antiretroviral therapy (ART).  On World AIDS Day, December 1, 2017, the NIH announced we are closer than ever to the beginning of the end of the HIV/AIDS pandemic. That’s why Southern Research has reaffirmed our commitment to support HIV/AIDS advancements from discovery to post-marketing surveillance. In this video, hear from Susan Schader, Ph.D., researcher for SR Drug Development, on the significance of HIV/AIDS research as we move into 2018.

Influenza Research

Infectious Disease Research News